RE:RE:RE:Is that a fake wall at .45.I think their motive is that as soon as the data from Phase 2 is sufficient enough to satisfy the FDA to provide TLT with the BTD accreditation, that means commercialization is a done deal and they (the potential acquirer) will make their move on TLT. They should already know exactly what we have, what the future revenue stream will be along with the NPV and will have ticked all of their boxes. They just need the proof statement that they can then justify to their board an approach/negotiation with TLT about takeover, JV or licensing deal. And the more they wait, the more they will have to pay.
They know that in order to be successful, the monetary compensation is going to have to be very, very large and there will need to be many variables factored in to consider future indications and trials. TLT is not going to give our trial success, patents and IP away for some lowball initial offer. The acquirer is only really going to get one serious shot at this opportunity and if they come up short, they will have lost their opportunity and momentum. The bidding from competitiors will get fierce from that point forward.
.